JPH09508009A - Fas抗原を結合するリガンド - Google Patents
Fas抗原を結合するリガンドInfo
- Publication number
- JPH09508009A JPH09508009A JP7518683A JP51868395A JPH09508009A JP H09508009 A JPH09508009 A JP H09508009A JP 7518683 A JP7518683 A JP 7518683A JP 51868395 A JP51868395 A JP 51868395A JP H09508009 A JPH09508009 A JP H09508009A
- Authority
- JP
- Japan
- Prior art keywords
- fas
- dna
- polypeptide
- protein
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ヒトFas−Lポリペプチドをコードしている単離DNAであって、該 Fas−Lポリペプチドが、N末端アミノ酸配列MQQPFNYPYPQIを特 徴とする上記単離DNA。 2. 前記DNAが、配列番号:1のヌクレオチド93〜128を含む5′配 列を特徴とする請求項1に記載の単離DNA。 3. 前記Fas−Lポリペプチドが、配列番号:2の残基1〜281のアミ ノ酸配列を含む請求項1に記載の単離DNA。 4. 前記DNAが、配列番号:1のヌクレオチド93〜938のヌクレオチ ド配列を含む請求項3に記載の単離DNA。 5. 前記DNAが、菌株ATCC69527で寄託された組換えベクターの cDNAインサートを含む請求項1に記載の単離DNA。 6. 前記DNAが、菌株ATCC69527で寄託された組換えベクターの cDNAインサートのコーディング領域を含む請求項1に記載の単離DNA。 7. 可溶性ヒトFas−Lポリペプチドをコードしている単離DNAであっ て、前記Fas−Lポリペプチドが、配列番号:2の残基106〜281のアミ ノ酸配列を含む上記単離DNA。 8. 前記DNAが、配列番号:1のヌクレオチド408〜938のヌクレオ チド配列を含む請求項7に記載の単離DNA。 9. 請求項1に記載のDNAを含む発現ベクター。 10.請求項2に記載のDNAを含む発現ベクター。 11.請求項3に記載のDNAを含む発現ベクター。 12.請求項6に記載のDNAを含む発現ベクター。 13.請求項7に記載のDNAを含む発現ベクター。 14.Fas−Lポリペプチドを製造する方法であって、請求項9に記載のベ クターによって形質転換された宿主細胞を、Fas−Lの発現を促進する条件下 で培養し、そして培養物からFas−Lポリペプチドを回収することを含む上記 方法。 15.Fas−Lポリペプチドを製造する方法であって、請求項10に記載の ベクターによって形質転換された宿主細胞を、Fas−Lの発現を促進する条件 下で培養し、そして培養物からFas−Lポリペプチドを回収することを含む上 記方法。 16.Fas−Lポリペプチドを製造する方法であって、請求項11に記載の ベクターによって形質転換された宿主細胞を、Fas−Lの発現を促進する条件 下で培養し、そして培養物からFas−Lポリペプチドを回収することを含む上 記方法。 17.Fas−Lポリペプチドを製造する方法であって、請求項12に記載の ベクターを含む宿主細胞を、Fas−Lの発現を促進する条件下で培養し、そし て培養物からFas−Lポリペプチドを回収することを含む上記方法。 18.Fas−Lポリペプチドを製造する方法であって、請求項13に記載の ベクターを含む宿主細胞を、Fas−Lの発現を促進する条件下で培養し、そし て培養物からFas−Lポリペプチドを回収することを含む上記方法。 19.N末端アミノ酸配列MQQPFNYPYPQIを特徴とする精製ヒトF as−Lタンパク質。 20.前記タンパク質が配列番号:2の残基1〜281のアミノ酸配列を含む 請求項19に記載のヒトFas−Lタンパク質。 21.配列番号:2の残基106〜281のアミノ酸配列を含む可溶性ヒトF as−Lタンパク質。 22.菌株ATCC69527で寄託された組換えベクターのcDNAインサ ートによってコードされたヒトFas−Lタンパク質。 23.請求項20に記載のFas−Lタンパク質と免疫反応性の抗体。 24.請求項21に記載のFas−Lタンパク質と免疫反応性の抗体。 25.前記抗体が単クローン性抗体である請求項23に記載の抗体。 26.前記抗体が単クローン性抗体である請求項24に記載の抗体。 27.配列番号:1のコーディンク領域の少なくとも約14個のヌクレオチド を含む単離核酸分子またはそのDNA若しくはRNA相補体。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17913894A | 1994-01-07 | 1994-01-07 | |
US19055994A | 1994-02-01 | 1994-02-01 | |
US179,138 | 1994-02-01 | ||
US190,559 | 1994-02-01 | ||
PCT/US1995/000362 WO1995018819A1 (en) | 1994-01-07 | 1995-01-06 | Ligand that binds fas antigen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004137823A Division JP2004290196A (ja) | 1994-01-07 | 2004-05-06 | Fas抗原を結合するリガンド |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09508009A true JPH09508009A (ja) | 1997-08-19 |
Family
ID=26875023
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7518683A Ceased JPH09508009A (ja) | 1994-01-07 | 1995-01-06 | Fas抗原を結合するリガンド |
JP2004137823A Pending JP2004290196A (ja) | 1994-01-07 | 2004-05-06 | Fas抗原を結合するリガンド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004137823A Pending JP2004290196A (ja) | 1994-01-07 | 2004-05-06 | Fas抗原を結合するリガンド |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0739350B1 (ja) |
JP (2) | JPH09508009A (ja) |
AT (1) | ATE387458T1 (ja) |
AU (1) | AU705484B2 (ja) |
CA (1) | CA2179909C (ja) |
DE (1) | DE69535719T2 (ja) |
NZ (1) | NZ279108A (ja) |
WO (1) | WO1995018819A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4734739B2 (ja) * | 2000-09-29 | 2011-07-27 | 東レ株式会社 | 哺乳動物のガン抑制方法 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
US6897295B1 (en) | 1993-11-10 | 2005-05-24 | Mochida Pharmaceutical Co., Ltd. | Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides |
US8715645B2 (en) | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
US5759536A (en) * | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
WO1996029350A1 (fr) * | 1995-03-20 | 1996-09-26 | Sumitomo Electric Industries, Ltd. | ANTICORPS MONOCLONAL REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas ET SON PROCEDE DE PRODUCTION |
CA2218685A1 (en) * | 1995-04-21 | 1996-10-24 | Ligand Pharmaceuticals Incorporated | Inhibition of apoptosis in cells expressing fas-ligand following activation |
US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
WO1997002290A1 (fr) * | 1995-06-30 | 1997-01-23 | Mochida Pharmaceutical Co., Ltd. | ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR |
US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
JPH09124509A (ja) * | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | 肝炎治療剤 |
GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
DE69730607T2 (de) | 1996-07-19 | 2005-01-27 | Takeda Chemical Industries, Ltd. | Fas ligand ähnliches protein, seine herstellung und verwendung |
WO1998010070A1 (fr) | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas |
DE19643093C2 (de) * | 1996-10-18 | 1998-10-01 | Apotech Sa | Verwendung von FasL oder mit FasL transfizierten CD4·+·/FasL·-·/TH1-Zellinien oder von FasL in Kombination mit einem oder mehreren Cytokin(en) zur Bekämpfung von TH1/TH2-Krankheiten |
EP1449539A2 (en) | 1996-10-31 | 2004-08-25 | Mochida Pharmaceutical Co., Ltd. | Prophylactic or therapeutic use of a Fas antagonist to inhibit Fas-mediated apoptosis |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
AU781104B2 (en) * | 1996-12-09 | 2005-05-05 | Regents Of The University Of California, The | Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
IL123888A0 (en) * | 1997-04-01 | 1998-10-30 | Sankyo Co | Anti-fas antibodies |
US7786282B2 (en) | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
BR0308401A (pt) | 2002-03-21 | 2005-03-29 | Lilly Co Eli | Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento. |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
US10772827B2 (en) | 2015-11-13 | 2020-09-15 | Industry-University Cooperation Foundation Hanyang University | Composition for treating apoplexy through nasal administration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010448A1 (en) * | 1990-01-19 | 1991-07-25 | German Cancer Research Center | A cell surface antigen associated with cellular apoptosis |
EP0510691B1 (en) * | 1991-04-26 | 2004-11-03 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
-
1995
- 1995-01-06 AT AT95907381T patent/ATE387458T1/de not_active IP Right Cessation
- 1995-01-06 JP JP7518683A patent/JPH09508009A/ja not_active Ceased
- 1995-01-06 CA CA2179909A patent/CA2179909C/en not_active Expired - Fee Related
- 1995-01-06 EP EP95907381A patent/EP0739350B1/en not_active Expired - Lifetime
- 1995-01-06 AU AU15632/95A patent/AU705484B2/en not_active Ceased
- 1995-01-06 WO PCT/US1995/000362 patent/WO1995018819A1/en active IP Right Grant
- 1995-01-06 DE DE69535719T patent/DE69535719T2/de not_active Expired - Lifetime
- 1995-01-06 NZ NZ279108A patent/NZ279108A/en not_active IP Right Cessation
-
2004
- 2004-05-06 JP JP2004137823A patent/JP2004290196A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4734739B2 (ja) * | 2000-09-29 | 2011-07-27 | 東レ株式会社 | 哺乳動物のガン抑制方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0739350A1 (en) | 1996-10-30 |
DE69535719D1 (de) | 2008-04-10 |
WO1995018819A1 (en) | 1995-07-13 |
NZ279108A (en) | 1997-06-24 |
CA2179909C (en) | 2010-04-27 |
EP0739350A4 (en) | 1998-09-23 |
JP2004290196A (ja) | 2004-10-21 |
CA2179909A1 (en) | 1995-07-13 |
AU705484B2 (en) | 1999-05-20 |
EP0739350B1 (en) | 2008-02-27 |
AU1563295A (en) | 1995-08-01 |
DE69535719T2 (de) | 2009-03-19 |
ATE387458T1 (de) | 2008-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09508009A (ja) | Fas抗原を結合するリガンド | |
JP3308534B2 (ja) | 新規なサイトカイン | |
JP4435304B2 (ja) | アポトーシスを誘導するサイトカイン | |
JP4138013B2 (ja) | Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド | |
US7211259B1 (en) | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides | |
US6974863B2 (en) | Antibody for 4-1BB | |
US5674704A (en) | Cytokine designated 4-IBB ligand | |
US7138500B1 (en) | Antibodies to human 4-1BB | |
JPH10502810A (ja) | Lerk−5と命名された新規のサイトカイン | |
JP4426724B2 (ja) | Ldcamと称される分子 | |
TW201636425A (zh) | 治療癌症之方法和組成物 | |
JPH07501941A (ja) | オンコスタチンmおよび白血病阻害因子の受容体 | |
JPH10512440A (ja) | サイトカイン”lerk−7” | |
US7014853B2 (en) | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) | |
JPH11503309A (ja) | Il−17受容体 | |
US7834157B2 (en) | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) | |
JP2002543787A (ja) | 白血球免疫グロブリン様受容体(lir)と命名された免疫調節因子のファミリー | |
JPH08507201A (ja) | リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用 | |
JP2001510042A (ja) | Trail受容体 | |
JP2002507127A (ja) | Trailに結合するタンパク質 | |
KR20160113268A (ko) | 이기능 융합단백질,이의 제조방법 및 용도 | |
JPH05500614A (ja) | 顆粒球コロニー刺激因子レセプター | |
JP2001521368A (ja) | Lerk―8と称すサイトカイン | |
MXPA98007441A (en) | Desired cytokine ler | |
JP2013005802A (ja) | Tnfスーパーファミリーのメンバーであるnf−kappabの受容体アクティベーターに対するリガンド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050531 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050905 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060110 |